Tag: Cellinity Battery

BioLargo expands PFAS, Clyra, and BLEST operations while working to recover from the financial fallout tied to Pooph®.

BioLargo enters early commercialization with Clyra and PFAS, but steep revenue loss from Pooph® collapse leaves execution and scaling critical in 2026.

BioLargo's Q3 2025 report shows tech traction in PFAS, Clyra™, and Cellinity™ — but monetization remains elusive post-Pooph® fallout.

BioLargo's Q2 exposes value-chain gaps—regulatory lags, partner dependency, and no clear path from validation to revenue.

BioLargo’s growth hinges on its AEC, Clyra™, and Pooph® innovations, but delays and cash burn turn Q2–Q3 into a critical test for its long-term ambitions.